Correction: Hanwha Asset Management - Not Hanwha Aerospace - Invests in Shield AI's $240M F-1 Round

2025-03-13 Shield AI HaiPress

WASHINGTON,March 13,2025 -- Shield AI is issuing a correction to its previously released announcement,"Shield AI raises $240M at $5.3B valuation to scaleHivemind Enterprise,an AI-powered autonomy developer platform."

The original release incorrectly identified Hanwha Aerospace as a participating investor. The correct entity is Hanwha Asset Management.

Shield AI apologizes for the error and appreciates the opportunity to clarify the correct information.

Media contact:

Lily Hinz,media@shield.ai

Logo - /up/2025/0313/25031320001166257178.jpg

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

2The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

6MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

Links

Handheld Inkjet Printer Australian Morning Post American fortune daily American People Network United States Newsletter BBC Network News American news network Startup Weekly New York City Morning Post Bloomberg Digital Journal Yahoo See industrial inkjet printer